Whereas in prostate cancer RLX promotes tumor progression via its effects on the protocadherin PCDHY18, the effects we described are mediated, at least in part, by increased expression of Wnt1 and reduced expression of Dkk1. Here, PCDH11X is linked to Familial prostate cancer.